Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lisaftoclax - Ascentage Pharma

Next Previous
Drug Profile

Lisaftoclax - Ascentage Pharma

Alternative Names: APG-2575

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascentage Pharma
  • Class Antineoplastics; Benzamides; Dioxanes; Piperazines; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma; Acute myeloid leukaemia; Multiple myeloma; Waldenstrom's macroglobulinaemia; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Phase I/II Acute myeloid leukaemia; Breast cancer; Multiple myeloma; Solid tumours
  • Phase I Myelodysplastic syndromes; Neuroblastoma
  • Preclinical Gastrointestinal stromal tumours; Non-small cell lung cancer
  • No development reported Diffuse large B cell lymphoma; Haematological malignancies

Most Recent Events

  • 27 Mar 2024 China CDE approves global registrational phase III trial for Olverembatinib in Acute myeloid leukaemia (First-line therapy, In the elderly)
  • 27 Mar 2024 Ascentage Pharma plans a phase III trial for Acute myeloid leukaemia (First-line therapy, In the elderly), prior to March 2024
  • 25 Mar 2024 Ascentage Pharma plans the phase III GLORA-2 trial in Chronic lymphocytic leukaemia (Combination therapy, Newly diagnosed) in China (PO), in April 2024 (NCT06319456)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top